Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. (PubMed, Clin Cancer Res) - Sep 29, 2026 - "Added benefit of CPI to PRRT for patients with high risk WD-NET remains unclear. SAE rate was higher than expected for PRRT alone."
Journal • Diabetes • Endocrine Disorders • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Solid Tumor • CD14 • CD8 • SSTR
|
|
Alexander Cheung; Arun Chumber; Bridget P Keenan; Ciara Benson; David Y Oh; Emily K Bergsland; Kiersten Tucker; Kira Chan; Lawrence Fong; Li Zhang; Nicholas Fidelman; Thomas A Hope
|